Hugel said Thursday that it has obtained product approval from Health Canada for its botulinum toxin (BTX) formulation, Letybo, which treats forehead wrinkles.The company had completed an on-site inspection of the Geodu plant, Hugel's botulinum toxin production base, to obtain a Canadian product lic
CG Bio said Thursday that the company signed contracts totaling 5.6 billion won ($4.3 million) with CarePlusOne of Taiwan and OTIMA of Brazil to export its anti-adhesion drug, Mediclore.Anti-adhesion agents prevent the adhesion of tissues or organs. After surgery, medical professionals insert it int
Korea’s major pharmaceutical and biopharmaceutical companies have published reports on their sustainability activities, including corporate social responsibility (CSR) and environment, social, and governance (ESG).On Wednesday, Hanmi Pharmaceutical issued the “2021-22 CSR Report” to explain the comp
Hanall Biopharma said it would exclusively sell Stavaster (ingredient: Rosuvastatin), a hyperlipidemia treatment developed by Sandoz Korea, Novartis' subsidiary for generic and biosimilar business.Hanall Biopharma will exclusively sell and promote Stavaster, and Sandoz Korea will supply it.Korea’s r
Effepharm said it has published the results of Uthever® Nicotinamide Mononucleotide (NMN) research on Frontier in Aging, an authoritative international journal on aging mechanisms.Uthever® NMN, an endogenous compound, has proved safe and improved the NAD+/NADH in the human body, thus realizing the a
A health expert recommended using pneumococcal vaccines, including Pfizer’s, for Covid-19 patients, noting that respiratory infection causes most of the hospitalization of those who developed sequelae even after a full recovery.The World Health Organization defines long Covid as cases that begin wit
Shinpoong Pharmaceutical, already working on multinational phase 3 trials of antimalarial treatment Pyramax in Covid-19 patients, said it would begin a new phase 2 study in Korea.The company said that the new study aims to confirm Pyramax’s effect against the Omicron variant.On Monday, the Ministry
HK inno.N said Tuesday that it has discovered next-generation immune-cancer antibodies in collaboration with Y Biologics. It added that the two companies would use this discovery to expand their research portfolio in antibody treatments and cell therapies such as CAR-T and CAR-NK.Antibodies are prot
Samsung Biologics said it would participate in the world’s largest biopharmaceutical exhibition, "2022 BIO International Convention,” from June 13-16 in San Diego, Calif., organized by the Biotechnology Innovation Organization.BIO holds the annual event in major U.S. cities with bio-clusters, provid
Dongkook Pharmaceutical said Monday it has signed a business agreement with Efil Bioscience to promote their joint research into new drugs.The two companies aim to develop promising new drugs, derive one or more non-clinical candidate substances by the end of this year, and conduct non-clinical rese
Pfizer Korea halted the supply of Vyndaqel Cap. 20 mg (Ingredient: Tafamidis), a transthyretin amyloid polyneuropathy (ATTR-PN) treatment, due to quality issues.The drug, which delays peripheral nerve damage in adult patients with stage 1 symptomatic polyneuropathy, has no substitute drug with the s
Ipsen Korea said it aims to provide a better treatment option for Korean renal cell cancer patients with a Cabometyx and Opdivo combination therapy after receiving approval to use the treatment as first-line therapy."Kidney cancer is a type of cancer difficult to detect at an early stage, and chemot
Dong-A ST said Friday that it has released non-clinical research results on the new drug candidate, DA-1726, in a poster session at the annual American Diabetes Association (ADA) conference.DA-1726 is a new drug under development as an oxyntomodulin analog-based obesity and diabetes treatment, which
Samsung Bioepis presented the phase 3 clinical trial results of its Soliris biosimilar, eculizumab (SB12), at the European Hematology Association 2022 (EHA2022) congress in Vienna on Friday.Soliris is a humanized monoclonal antibody produced in the NS0 cell line by recombinant DNA technology. It is
Sanofi-Aventis Korea’s labor union embarked on industrial action on Tuesday, as the wage negotiation with the management failed to narrow differences.According to the union, it has requested the management to reflect on the company’s improved sales performance last year on deciding this year’s wage
The European Medicines Agency (EMA) included Celltrion’s antibody treatment Regkirona (regdanvimab) in the list of critical medicines for Covid-19.EMA’s Medicines Shortages Steering Group (MSSG) adopted the list of critical drugs for the Covid-19 public health emergency on Tuesday, according to the
Eutilex said it would begin clinical trials for a CAR-T treatment to treat solid cancer for the first time in Korea.The company plans to submit an investigational new drug application (IND) for its CAR-T treatment pipeline in the second half of this year and has already secured non-clinical efficacy
Novartis said that the Ministry of Food and Drug Safety has approved Scemblix (Ingredient: asciminib), a treatment for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).Semblix treats adult patients with Ph+ CML in the chronic stages who have received treatment
Hanmi Pharmaceutical said Wednesday that the number of its drugs under development that have won orphan drug designations (ODD) has increased to 20, breaking its own record in the Korean biopharmaceutical industry.Most recently, Hanmi received an ODD from the European Medicines Agency (EMA) for LAPS
List Biotherapeutics, a U.S. subsidiary of Genome & Company, said that it has started the construction of its microbiome treatment production facility in Fishers City, Ind.Established in October 2020, List Biotherapeutics plans to build a large-scale microbiome production facility in Fishers Life Sc